HAEMATOLOGICA

Scope & Guideline

Pioneering Research in Hematology for Tomorrow's Advancements

Introduction

Delve into the academic richness of HAEMATOLOGICA with our guidelines, detailing its aims and scope. Our resource identifies emerging and trending topics paving the way for new academic progress. We also provide insights into declining or waning topics, helping you stay informed about changing research landscapes. Evaluate highly cited topics and recent publications within these guidelines to align your work with influential scholarly trends.
LanguageEnglish
ISSN0390-6078
PublisherFERRATA STORTI FOUNDATION
Support Open AccessYes
CountryItaly
TypeJournal
Convergefrom 1947 to 2024
AbbreviationHAEMATOLOGICA / Haematologica
Frequency12 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressVIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY

Aims and Scopes

HAEMATOLOGICA focuses on advancing the understanding and treatment of hematological conditions through innovative research methodologies and clinical studies. The journal aims to disseminate high-quality research that contributes to the field of hematology, including but not limited to leukemia, lymphoma, and related disorders.
  1. Clinical and Translational Research:
    HAEMATOLOGICA emphasizes clinical trials and translational studies that bridge laboratory findings with patient care, aiming to improve treatment protocols and patient outcomes in hematological malignancies.
  2. Molecular and Genomic Insights:
    The journal explores the genomic landscapes and molecular mechanisms underlying hematological diseases, providing insights into targeted therapies and their efficacy.
  3. Innovative Treatment Modalities:
    Research on new treatment strategies, including immunotherapy, CAR T-cell therapy, and novel pharmaceuticals, is a core focus, reflecting the journal's commitment to advancing therapeutic options for hematological patients.
  4. Patient-Centric Studies:
    The journal includes studies that assess quality of life and treatment adherence among patients, ensuring that research is aligned with the needs and experiences of individuals affected by blood disorders.
  5. Epidemiological and Public Health Perspectives:
    HAEMATOLOGICA also addresses the epidemiology of hematological diseases, including the impact of socio-economic factors and healthcare access on disease outcomes.
HAEMATOLOGICA has shown a robust evolution in its research themes, with several emerging topics gaining traction. These trends reflect the journal's responsiveness to new challenges and innovations in hematology.
  1. Immunotherapy and Targeted Therapies:
    There is a significant increase in studies focusing on immunotherapy, including CAR T-cell therapy and bispecific antibodies, as well as targeted therapies that aim to exploit specific genetic alterations in hematological malignancies.
  2. Minimal Residual Disease Monitoring:
    The importance of monitoring minimal residual disease (MRD) has gained prominence, with research focusing on its prognostic implications and its role in treatment decisions.
  3. Socioeconomic Factors and Health Disparities:
    Emerging research on how socioeconomic factors impact treatment outcomes and access to care in hematological malignancies is becoming more prevalent, highlighting the journal's commitment to patient-centered research.
  4. Microbiome and Hematology:
    Studies exploring the relationship between the microbiome and hematological diseases have emerged, reflecting a growing interest in how gut health may influence treatment responses and disease progression.
  5. Long-Term Outcomes and Survivorship:
    Research focusing on the long-term health outcomes and quality of life of hematology patients, particularly survivors of hematological malignancies, is increasingly featured, indicating a shift towards holistic patient care.

Declining or Waning

While HAEMATOLOGICA continues to thrive in various research areas, some themes have shown a decline in focus over recent years. This may indicate a shifting interest towards more contemporary issues or advancements in the field.
  1. Traditional Chemotherapy Studies:
    There has been a noticeable decrease in studies focusing solely on traditional chemotherapy regimens, as the field shifts towards exploring novel therapies and combinations that enhance efficacy and minimize toxicity.
  2. Basic Research Without Clinical Application:
    Studies that do not translate into clinical applications or lack direct relevance to patient outcomes are less frequently published, reflecting a trend towards more impactful research.
  3. Single-Agent Drug Studies:
    Research centered on single-agent therapies has waned, likely due to the increasing complexity of treatment regimens that involve combination therapies and personalized medicine.
  4. Elderly Patient Studies:
    Research specifically targeting elderly populations in hematology appears to be less prevalent, suggesting a potential gap in understanding the unique challenges faced by this demographic.

Similar Journals

Blood Advances

Innovating Blood Science for a Healthier Future
Publisher: ELSEVIERISSN: 2473-9529Frequency: 24 issues/year

Blood Advances is a premier, peer-reviewed journal published by Elsevier, dedicated to the field of hematology. With an impressive impact factor and classified within the Q1 category of hematology for 2023, it ranks as the 16th out of 137 journals in the Scopus Medicine Hematology category, placing it in the top 88th percentile globally. This influential journal, which has been disseminating invaluable research since its inception in 2017, focuses on advancing knowledge and innovation in blood science, including clinical and laboratory aspects of hematology. Although it offers limited open access features, its comprehensive scope encompasses various topics relevant to both researchers and practitioners. Located in the United States and managed from Amsterdam, Blood Advances provides a vital platform for the dissemination of groundbreaking research, making significant contributions to the understanding and treatment of blood disorders. Researchers, professionals, and students alike will find this journal an essential resource for keeping abreast of the latest developments and advancements in hematology.

ACTA HAEMATOLOGICA

Driving Excellence in Blood Science Research
Publisher: KARGERISSN: 0001-5792Frequency: 6 issues/year

ACTA HAEMATOLOGICA, published by KARGER, is a prestigious journal established in 1948, dedicated to the field of hematology and related medical sciences. With an ISSN of 0001-5792 and an E-ISSN of 1421-9662, this journal stands out with a Q2 ranking in both Hematology and Miscellaneous Medicine categories as of 2023. Researchers and professionals can benefit from its high-quality peer-reviewed articles, contributing to a more profound understanding and advancement of hematological practices. Although it does not offer open access options, ACTA HAEMATOLOGICA remains an essential resource for researchers in Switzerland and worldwide, providing critical insights and fostering discourse among academic and clinical communities. The journal's address is located in the heart of Basel, Switzerland, ensuring its robust connection to European medical research networks. With a firm commitment to excellence, this publication plays a vital role in disseminating knowledge, guiding future innovations in the field.

INTERNATIONAL JOURNAL OF HEMATOLOGY

Exploring Breakthroughs in Blood Disorders
Publisher: SPRINGER JAPAN KKISSN: 0925-5710Frequency: 12 issues/year

The INTERNATIONAL JOURNAL OF HEMATOLOGY, published by SPRINGER JAPAN KK, serves as a critical platform for advancing research in the field of hematology. With a prestigious history spanning over three decades from 1991 to 2024, this journal is recognized for its impactful contributions, evidenced by its Q2 category ranking in Hematology for 2023, and its notable position at rank #71 out of 137 in the Scopus Medicine Hematology category. Researchers and professionals within the hematology community benefit from the journal's rigorous peer-reviewed articles that cover a wide range of topics, including clinical studies, basic research, and novel therapeutic strategies. Though currently non-open access, it provides essential insights and findings to an audience passionate about the latest advancements in blood disorders and treatments. Situated in Japan, the journal not only showcases high-quality research but also fosters a global exchange of knowledge in hematology, making it a significant resource for scholars, practitioners, and students alike.

BLOOD REVIEWS

Elevating knowledge in blood disorders and cancer care.
Publisher: CHURCHILL LIVINGSTONEISSN: 0268-960XFrequency: 6 issues/year

BLOOD REVIEWS is a highly regarded journal published by Churchill Livingstone, specializing in the fields of Hematology and Oncology. With an impressive Q1 ranking in both disciplines and placing in the top 10% of its peer categories according to Scopus metrics, it provides an essential platform for the dissemination of cutting-edge research and reviews pertaining to blood disorders and cancer treatment. Since its inception in 1987 and continuing through 2024, the journal has established itself as a cornerstone for healthcare professionals, researchers, and students who seek to advance their understanding of hematologic and oncologic topics. While not an open-access journal, BLOOD REVIEWS retains a reputation for delivering high-quality, peer-reviewed articles that foster dialogue and innovation within the scientific community. For those in the United States and beyond, the journal serves as a vital resource, housed at the Journal Production Department in Edinburgh, Scotland, ensuring accessibility and a global reach in its critical academic contributions.

EUROPEAN JOURNAL OF HAEMATOLOGY

Elevating Knowledge in Hematology Since 1986
Publisher: WILEYISSN: 0902-4441Frequency: 12 issues/year

EUROPEAN JOURNAL OF HAEMATOLOGY, published by Wiley, serves as a vital resource for experts in the field of hematology, focusing on the latest advancements in blood disorders and therapies. With an ISSN of 0902-4441 and an E-ISSN of 1600-0609, this esteemed journal has been disseminating knowledge since 1986 and continues to thrive, converging its visionary approach through to 2024. Notably, it holds a distinguished Q2 ranking in Hematology and an impressive Q1 ranking in the broader category of Medicine (miscellaneous) as of 2023, highlighting its significant contribution to the scientific community. With a Scopus rank of #45/137 and a 67th percentile in the field, the journal is recognized for its rigorous peer-reviewed research, making it an indispensable publication for researchers, practitioners, and students aiming to stay at the forefront of hematological studies. Though not an open-access journal, it ensures broad accessibility to critical findings via its subscription model, thus fostering an informed and globally engaged audience.

Blood Cancer Discovery

Pioneering Discoveries for a Cancer-Free Tomorrow
Publisher: AMER ASSOC CANCER RESEARCHISSN: 2643-3230Frequency: 6 issues/year

Blood Cancer Discovery is a premier academic journal published by the American Association for Cancer Research, dedicated to advancing the understanding of hematologic malignancies through cutting-edge research in the fields of oncology, biochemistry, and molecular biology. With an impressive impact factor and recognition as a Q1 journal across multiple disciplines, including cancer research and hematology, Blood Cancer Discovery serves as an essential platform for scholars and practitioners alike, facilitating impactful discourse and dissemination of pioneering findings. This open-access journal, established within the vibrant academic landscape of the United States, aims to bridge gaps in research and foster collaborations to ultimately enhance patient outcomes. Its Scopus rankings demonstrate its vital role in the critical advancement of cancer research and therapeutic development. By inviting contributions from a diverse range of disciplines, Blood Cancer Discovery is poised to drive innovation and inspire future advancements in understanding blood cancers.

BLOOD

Transforming Insights into Blood Science.
Publisher: AMER SOC HEMATOLOGYISSN: 0006-4971Frequency: 52 issues/year

BLOOD, published by the American Society of Hematology, is a premier peer-reviewed journal in the fields of Biochemistry, Cell Biology, Hematology, and Immunology. With an impressive impact factor and ranking in the top quartiles (Q1) across multiple disciplines, BLOOD is essential reading for researchers and professionals seeking to stay updated on the latest advancements in hematology and related fields. The journal has been a cornerstone of hematological research since its inception in 1946, providing a platform for rigorous scientific inquiry and discourse. Its commitment to publishing high-quality original research, comprehensive reviews, and insightful editorials makes it a vital resource for students, practitioners, and scientists alike. By offering exceptional access to influential publications, BLOOD continues to shape the future of hematology and enhance understanding of blood-related disorders, marking its vital role in advancing both basic and clinical research.

Turkish Journal of Hematology

Advancing hematological research for a healthier tomorrow.
Publisher: GALENOS PUBL HOUSEISSN: 1300-7777Frequency: 4 issues/year

Turkish Journal of Hematology is an esteemed publication dedicated to advancing the field of hematology, producing influential research since its inception in 1999 under the auspices of GALENOS PUBL HOUSE. With an Open Access model, it facilitates widespread dissemination of knowledge, allowing researchers, clinicians, and students to stay abreast of the latest developments in blood disorders and treatments. With an ISSN of 1300-7777 and an E-ISSN of 1308-5263, the journal holds a commendable position in the academic community, evidenced by its 2023 Q3 ranking within the hematology category and its standing at #80 out of 137 in the Scopus database, placing it in the 41st percentile. Covering a wide scope of topics within hematology, this journal serves as a critical resource for disseminating innovative research and clinical practices pertinent to the ongoing challenges faced in this vital area of medicine. With its continuous publication until 2024, Turkish Journal of Hematology remains a beacon for enhancing the understanding and treatment of hematological conditions within the Turkish and global medical communities.

Blood and Lymphatic Cancer-Targets and Therapy

Fostering Collaboration for Breakthrough Cancer Solutions
Publisher: DOVE MEDICAL PRESS LTDISSN: 1179-9889Frequency: 1 issue/year

Blood and Lymphatic Cancer-Targets and Therapy, published by DOVE MEDICAL PRESS LTD, is a vital open-access journal that has been disseminating crucial research and findings in the field of hematology and oncology since 2011. With its ISSN 1179-9889, this journal focuses on the latest therapeutic targets and innovative treatment strategies for blood and lymphatic cancers, contributing significantly to the advancement of knowledge and practice in this specialized area. Designed for researchers, healthcare professionals, and students alike, Blood and Lymphatic Cancer-Targets and Therapy aims to foster a deeper understanding of cancer biology and promote collaborative efforts leading to novel therapeutic interventions. The open-access model ensures that research findings are readily accessible to a global audience, underscoring the journal's commitment to enhancing patient care and fostering educational growth in the cancer domain.

Indian Journal of Hematology and Blood Transfusion

Inspiring Progress in Blood Health Through Rigorous Research
Publisher: SPRINGER INDIAISSN: 0971-4502Frequency: 4 issues/year

Indian Journal of Hematology and Blood Transfusion, published by SPRINGER INDIA, serves as a leading platform for disseminating original research, reviews, and case studies in the field of hematology. With an ISSN of 0971-4502 and E-ISSN 0974-0449, this journal has been instrumental in advancing knowledge from 2000 to 2024, providing insights into critical issues surrounding blood disorders and transfusion practices. Currently ranked in the Q3 category for Hematology for 2023, it reflects a commitment to high-quality scientific content amidst a competitive landscape where it ranks 97/137 in Scopus for Medicine - Hematology, placing it in the 29th percentile of its peers. The journal primarily addresses a diverse readership, including researchers, healthcare professionals, and students, aiming to foster innovation and collaboration within the field. Although it operates under a subscription model, access options for individual articles and institutional subscriptions ensure that valuable research is disseminated widely to enhance medical practice and education in hematology.